Huayi Biology

Huayi Biology (Huayi Lejian) is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of transformative gene therapies. The company was founded by Professor Rao Yi, a distinguished neurobiologist and educator, to translate cutting-edge research into clinical solutions for rare and chronic diseases. Huayi Biology utilizes a proprietary Adeno-associated virus (AAV) platform specifically optimized for liver-targeted delivery and high-efficiency expression. Its lead candidate, HY-001, is currently undergoing clinical evaluation for the treatment of Hemophilia A. With a robust pipeline targeting hematological and metabolic disorders, the company aims to establish itself as a leader in the global gene therapy landscape.